Immunic Inc. (IMUX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 7 wire items for IMUX, including 4 press releases and news items, 1 leadership change and 1 analyst rating. The most recent was published Nov 2, 2026.
IMUX rankings
Financial highlights
Full financials- Net income, TTM
- -$111.57M
- Free cash flow, TTM
- -$88.05M
- Cash
- $155.10M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks57+50%
2026-05-102026-11-01
Mix2390d
- SEC Filings6(26%)
- Other6(26%)
- Leadership4(17%)
- Insider4(17%)
- Analyst2(9%)
- 13D/G1(4%)
Latest news
25 items- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Immunic Inc.SCHEDULE 13G/A - IMMUNIC, INC. (0001280776) (Subject)
- PRImmunic to Participate in Investor Conferences in NovemberNEW YORK, Nov. 2, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor conferences in November:November 9-11: Guggenheim 3rd Annual Healthcare Innovation Conference. Erik Lundgren, Chief Executive Officer, and Jason Tardio, President and Chief Operating Officer, will participate in a fireside chat on Monday, November 9, 2026 at 1:00 pm ET at this conference in Boston. A webcast will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.Mr. Lundgren, Mr. Tardio,
- PRImmunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a virtual Research and Development (R&D) Day focused on progressive multiple sclerosis (MS) on Thursday, November 5, 2026, at 12:30 pm ET.In addition to members of Immunic's management team, including Erik Lundgren, M.B.A., Chief Executive Officer, Michael A. Panzara, M.D., M.P.H., Chief Medical Officer, Hella Kohlhof, Ph.D., Chief Scientific Officer, and Jason Tardio, M.B.A., President & Chief Operating Officer, the event will feature presentations by two renowned experts in the t
- ANALYSTCantor Fitzgerald initiated coverage on ImmunicCantor Fitzgerald initiated coverage of Immunic with a rating of Overweight
- PRImmunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting– New Phase 2 CALLIPER Open-Label Extension Data Support Durability of Disability Outcomes Observed During the Double-Blind Period With Continued Vidofludimus Calcium Treatment; Safety and Tolerability Profile Appeared Consistent With That Observed in the Double-Blind Period –– New Preclinical Data Suggest Nurr1-Dependent Neuronal Survival and Neuroprotective Effects Beyond DHODH Inhibition –– Exploratory and Post-hoc CALLIPER Analyses Show Significant Reductions in EBV-Specific T-Cell Receptor Signatures; Observed Reductions Associated With Increased Symbol Digit Modalities Test (SDMT) Scores –– Post-hoc Analysis of CALLIPER Using a Proposed Novel Disability Measure Suggests Overall Benefit
- PRImmunic Appoints Jaa Roberson as Chief People Officer– Appointment Supports Immunic's Strategy to Build a Leading Multiple Sclerosis Organization Ahead of Potential Transition to Fully Integrated Commercial Company –NEW YORK, Oct. 19, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Jaa Roberson as Chief People Officer (CPO), effective today. Ms. Roberson will report directly to Chief Executive Officer Erik Lundgren and will serve as a member of the executive leadership team.The appointment represents another important step in Immunic's strategy to assemble a team of highly qualified leaders with ke
- PRImmunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting– Four Accepted Abstracts Further Characterize Investigational Vidofludimus Calcium's Profile in Multiple Sclerosis Across Long-Term Disability Outcomes, EBV-Related Immune Activity and Cognition, Novel Disability Measurement, and Nurr1-Mediated Neuronal Survival –– New Phase 2 CALLIPER Open-Label Extension Data Show Disability Outcomes Favoring Continuous Vidofludimus Calcium Treatment Maintained Through Extension Week 48, With Low Treatment Discontinuation –NEW YORK, Oct. 7, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that four abstracts highlighting new clin
- SECSEC Form S-8 filed by Immunic Inc.S-8 - IMMUNIC, INC. (0001280776) (Filer)
- INSIDERSEC Form 4 filed by Director Nagel Robert Thorvald4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 4 filed by See Explanation of Responses Bvf Partners L P/Il4 - IMMUNIC, INC. (0001280776) (Issuer)
- SECImmunic Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - IMMUNIC, INC. (0001280776) (Filer)
- SECImmunic Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a virtual research and development (R&D) day focused on relapsing multiple sclerosis (MS) on Wednesday, September 9, 2026, at 11:00 am ET.Management of Immunic, including Erik Lundgren, M.B.A., Chief Executive Officer, Michael A. Panzara, M.D., M.P.H., Chief Medical Officer, Hella Kohlhof, Ph.D., Chief Scientific Officer, and Jason Tardio, M.B.A., President & Chief Operating Officer, will be joined by two renowned key opinion leaders, Amit Bar-Or, M.D., FRCPC, Perelman School of Me
- PRImmunic Appoints Chitrang Davé as Chief Data and Digital Officer– New C-Suite Role and Appointment Underscore Commitment to Building a Strong, Commercial-Ready Data Ecosystem, in Preparation for Potential NDA Submission and Commercialization –NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Chitrang Davé as Chief Data and Digital Officer (CDDO), effective today. Mr. Davé will report directly to Chief Executive Officer Erik Lundgren and will serve as a member of the executive leadership team.In this newly created C-suite role, Mr. Davé will establish and lead Immunic's enterprise-wide data sy
- ANALYSTWedbush initiated coverage on Immunic with a new price targetWedbush initiated coverage of Immunic with a rating of Outperform and set a new price target of $45.00
- SECSEC Form SCHEDULE 13G filed by Immunic Inc.SCHEDULE 13G - IMMUNIC, INC. (0001280776) (Subject)
- SECSEC Form S-8 filed by Immunic Inc.S-8 - IMMUNIC, INC. (0001280776) (Filer)
- SECImmunic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - IMMUNIC, INC. (0001280776) (Filer)
- SECSEC Form 10-Q filed by Immunic Inc.10-Q - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness –– Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track, with Top-Line Data Expected by End of 2026 –– Continued Preparations for Phase 3 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis, with Initiation Planned Later This Year –NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today r
- INSIDERSEC Form 4 filed by Director Ridloff Elena4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ridloff Elena3 - IMMUNIC, INC. (0001280776) (Issuer)
- PRImmunic Appoints Elena Ridloff to Board of Directors– Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in Relapsing Multiple Sclerosis as well as Potential Regulatory Filings and Commercialization –NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Elena Ridloff, CFA to its Board of Directors, effective August 6, 2026. Ms. Ridloff brings more than two decades of experience driving financial strategy, corporate growth, and capital markets execution across the biopharmaceutical i
- SECImmunic Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic to Participate in Investor Conferences in JulyNEW YORK, July 9, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor conferences in July:July 14-15: Leerink Partners Therapeutics Forum. Erik Lundgren, Chief Executive Officer, Jason Tardio, President and Chief Operating Officer, Michael A. Panzara, M.D., M.P.H., Chief Medical Officer and Jessica Breu, Vice President Investor Relations and Communications at Immunic, will participate in one-on-one investor meetings at this conference in Boston. To schedule a meeting, please contact your Leerink representative or Jessica Breu at:
IMUX FAQ
10 questionsWhat does Immunic Inc. do?
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from...What is the latest news on IMUX?
In the last 30 days Quantisnow tracked 7 wire items for IMUX: 4 press releases and news items, 1 leadership change, 1 analyst rating and 1 13D/G filing. The most recent was published on November 2, 2026.Is IMUX profitable?
No. Immunic Inc. reported a net loss of $111.57M for the twelve months ended Jun 30, 2026.How much cash and debt does IMUX have?
Immunic Inc. reported $155.10M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does IMUX stock trade?
Immunic Inc. (IMUX) is listed on NASDAQ.What sector and industry is IMUX in?
Immunic Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Immunic Inc. go public?
Immunic Inc. (IMUX) completed its IPO in 2014.What are analysts saying about IMUX?
Across the last 8 analyst actions on Immunic Inc., there were 0 upgrades and 1 downgrade. The most recent action was from Cantor Fitzgerald: Overweight on 2026-10-23.What companies are similar to IMUX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IMUX side-by-side with any of them on Quantisnow.How can I track IMUX on Quantisnow?
Quantisnow aggregates Immunic Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMUX to receive live email and push alerts on every new disclosure.